Background:  Cyclic AMP dependent phosphodiesterase type D (PDE4D) family is comprised of 5 variants (PDE4D1, D2, D3, D4, D6, D7, and D8; 1, 2). One or more PDE4D subtype variants are ubiquitously present in all mammalian cells. In CNS all five PDE4D subtype variants are expressed in varying ratios, and their activity is regulated in tandem with GPCRs stimulation and selective phosphorylation by PKA and other kinases. Peripheral tissues also exhibit differential expression of PDE4D variants. PDE4D1/D2 mRNA levels rise in response to an increase in cAMP. Short term regulation of PDE4D variants involved PKA, MAP kinases and Erk2 phosphorylation that results in rapid change in their enzymatic activities. Other regulatory mechanism involved protein protein interactions with cytoskeletal scaffolding proteins. Anti PDE4D antibodies are ideal tools for studying regulation, expression, phosphorylation, and protein protein interactions of PDE4D variants employing pull down immunoprecipitation protocol.

Description: Rabbit polyclonal to PDE4D7

Immunogen: KLH conjugated synthetic peptide derived from PDE4D7

Specificity:  ·Reacts with Human, Mouse and Rat.

·Isotype: IgG

Application:  ·Western blotting: 1/100-500. Predicted Mol wt: 110 kDa;

·Immunohistochemistry (Paraffin/frozen tissue section): 1/100-200;

·Immunocytochemistry: 1/100;

·Immunoprecipitation: 1/50;

·ELISA: 1/500;

·Optimal working dilutions must be determined by the end user.